Previous close | 0.3900 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 130.00 |
Expiry date | 2024-06-21 |
Day's range | 0.2800 - 0.3900 |
Contract range | N/A |
Volume | |
Open interest | 1.77k |
A subsidiary of Johnson & Johnson is now proposing to pay approximately $6.48 billion over 25 years as part of a settlement in the U.S. to cover allegations that its baby powder containing talc caused ovarian cancer. The lawsuits filed against J&J had alleged its talcum powder caused users to develop ovarian cancer, through use for feminine hygiene, or mesothelioma, a cancer that strikes the lungs and other organs. The claims contributed to drop in J&J’s sales of baby powder, prompting the company to stop selling its talc-based products in 2020.
Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer, the company said Wednesday in a statement. The deal would allow it to resolve the lawsuits through a third bankruptcy filing of a subsidiary company. It will begin a three month voting period in hopes of reaching consensus on a settlement of all current and future ovarian cancer claims.
Johnson & Johnson on Wednesday unveiled its latest effort to put to rest the sweeping litigation it has faced over alleged injuries caused by its talc products, offering deals under which it would pay roughly $11 billion to various groups of plaintiffs. The talc lawsuits have dogged Johnson & Johnson for years. Earlier efforts to settle the claims involving complex maneuverings in bankruptcy court system have repeatedly failed.